Alector has completed subject enrolment in the Phase II trial of AL101/GSK4527226 in individuals with early Alzheimer's ...

The Sabin Vaccine Institute has begun a trial to evaluate its Marburg vaccine, with the first doses being given to subjects ...

The EMA has approved Cullinan Therapeutics’ clinical trial application for CLN-978, a drug intended to treat rheumatoid ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Hoth Therapeutics has reported interim data from a trial of HT-001, a drug designed for treating pruritus associated with ...

An independent Data Safety Monitoring Board (DSMB) has recommended the continuation of BioCardia's Phase I/II CardiALLO-HF ...

Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member ...

Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US FDA for the trial of ...

Genesis has gained US Food and Drug Administration (FDA) clearance on an Investigational New Drug (IND) application for a ...

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for PHST001, aimed at treating advanced ...

More than just a tool for advancing pipelines, trial efficiency is the name of the game when it comes to synthetic control ...

Alzheon's Alzheimer's drug showed nominal benefit in a subgroup of patients who suffer with mild cognitive impairment.